PURPOSE: To identify papillary thyroid carcinoma (PTC)-associated transcripts, we compared the gene expression profiles of three Serial Analysis of Gene Expression libraries generated from thyroid tumors and a normal thyroid tissue. EXPERIMENTAL DESIGN: Selected transcripts were validated in a panel of 57 thyroid tumors using quantitative PCR (qPCR). An independent set of 71 paraffin-embedded sections was used for validation using immunohistochemical analysis. To determine if PTC-associated gene expression could predict lymph node involvement, a separate cohort of 130 primary PTC (54 metastatic and 76 nonmetastatic) was investigated. The BRAF(V600E) mutational status was compared with qPCR data to identify genes that might be regulated by abnormal BRAF/MEK/extracellular signal-regulated kinase signaling. RESULTS: We identified and validated new PTC-associated transcripts. Three genes (CST6, CXCL14, and DHRS3) are strongly associated with PTC. Immunohistochemical analysis of CXCL14 confirmed the qPCR data and showed protein expression in PTC epithelial cells. We also observed that CST6, CXCL14, DHRS3, and SPP1 were associated with PTC lymph node metastasis, with CST6, CXCL14, and SPP1 being positively correlated with metastasis and DHRS3 being negatively correlated. Finally, we found a strong correlation between CST6 and CXCL14 expression and BRAF(V600E) mutational status, suggesting that these genes may be induced subsequently to BRAF activation and therefore may be downstream in the BRAF/MEK/extracellular signal-regulated kinase signaling pathway. CONCLUSION: CST6, CXCL14, DHRS3, and SPP1 may play a role in PTC pathogenesis and progression and are possible molecular targets for PTC therapy.
PURPOSE: To identify papillary thyroid carcinoma (PTC)-associated transcripts, we compared the gene expression profiles of three Serial Analysis of Gene Expression libraries generated from thyroid tumors and a normal thyroid tissue. EXPERIMENTAL DESIGN: Selected transcripts were validated in a panel of 57 thyroid tumors using quantitative PCR (qPCR). An independent set of 71 paraffin-embedded sections was used for validation using immunohistochemical analysis. To determine if PTC-associated gene expression could predict lymph node involvement, a separate cohort of 130 primary PTC (54 metastatic and 76 nonmetastatic) was investigated. The BRAF(V600E) mutational status was compared with qPCR data to identify genes that might be regulated by abnormal BRAF/MEK/extracellular signal-regulated kinase signaling. RESULTS: We identified and validated new PTC-associated transcripts. Three genes (CST6, CXCL14, and DHRS3) are strongly associated with PTC. Immunohistochemical analysis of CXCL14 confirmed the qPCR data and showed protein expression in PTC epithelial cells. We also observed that CST6, CXCL14, DHRS3, and SPP1 were associated with PTC lymph node metastasis, with CST6, CXCL14, and SPP1 being positively correlated with metastasis and DHRS3 being negatively correlated. Finally, we found a strong correlation between CST6 and CXCL14 expression and BRAF(V600E) mutational status, suggesting that these genes may be induced subsequently to BRAF activation and therefore may be downstream in the BRAF/MEK/extracellular signal-regulated kinase signaling pathway. CONCLUSION:CST6, CXCL14, DHRS3, and SPP1 may play a role in PTC pathogenesis and progression and are possible molecular targets for PTC therapy.
Authors: Y Huang; M Prasad; W J Lemon; H Hampel; F A Wright; K Kornacker; V LiVolsi; W Frankel; R T Kloos; C Eng; N S Pellegata; A de la Chapelle Journal: Proc Natl Acad Sci U S A Date: 2001-12-18 Impact factor: 11.205
Authors: Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend Journal: Nature Date: 2002-01-31 Impact factor: 49.962
Authors: Edna T Kimura; Marina N Nikiforova; Zhaowen Zhu; Jeffrey A Knauf; Yuri E Nikiforov; James A Fagin Journal: Cancer Res Date: 2003-04-01 Impact factor: 12.701
Authors: Thomas J Giordano; Rork Kuick; Dafydd G Thomas; David E Misek; Michelle Vinco; Donita Sanders; Zhaowen Zhu; Raffaele Ciampi; Michael Roh; Kerby Shedden; Paul Gauger; Gerard Doherty; Norman W Thompson; Samir Hanash; Ronald J Koenig; Yuri E Nikiforov Journal: Oncogene Date: 2005-10-06 Impact factor: 9.867
Authors: Fabio Cerignoli; Xiaojia Guo; Beatrice Cardinali; Christian Rinaldi; Jessica Casaletto; Luigi Frati; Isabella Screpanti; Lorraine J Gudas; Alberto Gulino; Carol J Thiele; Giuseppe Giannini Journal: Cancer Res Date: 2002-02-15 Impact factor: 12.701
Authors: Paula Soares; Vítor Trovisco; Ana Sofia Rocha; Jorge Lima; Patrícia Castro; Ana Preto; Valdemar Máximo; Tiago Botelho; Raquel Seruca; Manuel Sobrinho-Simões Journal: Oncogene Date: 2003-07-17 Impact factor: 9.867
Authors: Janete M Cerutti; Gisele Oler; Pedro Michaluart; Rosana Delcelo; Robert M Beaty; Jennifer Shoemaker; Gregory J Riggins Journal: Cancer Res Date: 2007-08-15 Impact factor: 12.701
Authors: Cléber P Camacho; Susan C Lindsey; Maria Clara C Melo; Ji H Yang; Fausto Germano-Neto; Flávia de O F Valente; Thiago R N Lima; Rosa Paula M Biscolla; José G H Vieira; Janete M Cerutti; Magnus R Dias-da-Silva; Rui M B Maciel Journal: Thyroid Date: 2013-03 Impact factor: 6.568
Authors: Robert C Smallridge; Ana-Maria Chindris; Yan W Asmann; John D Casler; Daniel J Serie; Honey V Reddi; Kendall W Cradic; Michael Rivera; Stefan K Grebe; Brian M Necela; Norman L Eberhardt; Jennifer M Carr; Bryan McIver; John A Copland; E Aubrey Thompson Journal: J Clin Endocrinol Metab Date: 2013-12-02 Impact factor: 5.958